Illusions of safety: Antimutagens can be mutagens, and anticarcinogens can be carcinogens

Mutation Research - Reviews in Mutation Research

Volumn 543, Issue 3, 2003, Pages 191-194

  Zeiger, Errol ^a  

^a Errol Zeiger Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMUTAGENIC AGENT; ANTINEOPLASTIC AGENT; CARCINOGEN;

ACCURACY; APOPTOSIS; CANCER INCIDENCE; CARCINOGENESIS; CARCINOGENICITY; CELL FUNCTION; CHROMOSOME ABERRATION; CONCENTRATION (PARAMETERS); DIET; DROSOPHILA; ELECTRON; GENE MUTATION; HUMAN; IN VITRO STUDY; MEDICAL INFORMATION; MEDICAL LITERATURE; MUTAGENESIS; MUTAGENICITY; NONHUMAN; NOTE; OXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; TUMOR CELL; YEAST;

EID: 0037674662     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(02)00111-4     Document Type: Note

References (16)

1. von Borstal R.C., Higgins J.A. Janus carcinogens and mutagens. Mutat. Res. 402:1998;321-329.
2. M. Paolini, S.Z. Abdel-Rahman, A. Sapone, G.F. Pedulli, P. Perocco, G. Cantelli-Forti, M.S. Legator, Beta-carotene: a cancer chemopreventive agent or a co-carcinogen? Mutat. Res.,
3. The Alpha-Tocopherol, Beta-Carotene Prevention Study Group: the effect of Vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers, New Engl. J. Med. 330 (1994) 1029-1035.
4. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens J.P. Jr., Valanis B., Williams J.H. Jr., Barnhart S., Cherniack M.G., Brodkin C.A., Hammar S. Risk factors for lung cancer and for intervention effects in CARET: the beta-carotene and retinol efficacy trial. J. Natl. Cancer Inst. 88:1996;1550-1559.
5. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., Hammar S. Effects of a combination of beta-carotene and Vitamin A on lung cancer and cardiovascular disease. New Engl. J. Med. 234:1996;1150-1155.
6. Dashwood R.H. Modulation of heterocyclic amine-induced mutagenicity and carcinogenicity: an 'A-to-Z' guide to chemopreventive agents, promoters, and transgenic models. Mutat. Res. 511:2002;89-112.
7. Waters M.D., Stack H.F., Jackson M.A., Brockman H.E., De Flora S. Activity profiles of antimutagens: in vitro and in vivo data. Mutat. Res. 350:1996;109-129.
8. Fahrig R. Antimutagenic agents are also co-recombinogenic and can be converted to co-mutagens. Mutat. Res. 350:1996;59-67.
9. Kaya B., Creus A., Velazquez A., Yanikoglu A., Marcos R. Genotoxicity is modulated by ascorbic acid: studies using the wing spot test in Drosophila. Mutat. Res. 520:2002;93-101.
10. Stich H.F., Karim J., Koropatnick J., Lo L. Mutagenic action of ascorbic acid. Nature. 260:1976;722-724.
11. Galloway S.M., Painter R.B. Vitamin C is positive in the DNA synthesis inhibition and sister-chromatid exchange tests. Mutat. Res. 60:1979;321-327.
12. P.H.M. Lohman, J.M. Gentile, G. Gentile, L.R. Ferguson (Eds.), Antimutagenesis/anticarcinogenesis: screening, methods and biomarkers, Mutat. Res. 496 (2001) 228.
13. Jang J.-H., Surh Y.-J. Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat. Res. 496:2001;181-190.
14. Seo H.-J., Surh Y.-J. Eupatilin: a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human promyelocytic leukemia cells. Mutat. Res. 496:2001;191-198.
15. Matsuoka A., Takeshita K., Furuta A., Ozaki M., Fukuhara K., Miyata N. The 4′-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mutat. Res. 521:2002;29-35.
16. Zeiger E. Death and antimutagenicity. Mutat. Res. 466:2000;125-127.